Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

Written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.

Acinar adenocarcinoma (inclusive neuro-endocrine dedifferentiation).

Oligoprogressive disease on conventional imagine within a maximum of 6 weeks prior to randomisation defined as: a maximum of 3 extracranial progressive lesions (pre-existing lesions, the development of new lesions, or both) in any organ. Nodal (N1) disease should be measured in the short axis. Nodes more than 1.5 cm in the short axis are considered pathologic and measurable. Oligoprogression on bone scan is defined as the occurrence of maximal 3 new and/or progressive lesions. In case of not unambiguously, additional imaging such as diagnostic magnetic resonance imaging (MRI) or dedicated CT-scan should be performed. Visceral disease reported separately (lung, liver, adrenal, or CNS) and is considered measurable if an individual lesions is more than 1 cm longest dimension.

Patients with oligoprogressive disease with pADT only as ongoing treatment (Type 1).